Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.36 |
| ▸ | WDR5 | P61964 | 4/20 | 0.35 |
| ▸ | DRD2 | P14416 | 5/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31079167 | 0.90 | ASIC3 (0.45) | ASIC3WDR5PDE3BPDE3A | |
| SCHEMBL29964608 | 0.87 | FGFR1 (0.39) | TLR7DRD2MAPKAPK2 | |
| SCHEMBL29964191 | 0.86 | CCNT1 (0.38) | ASIC3PDE3BPDE3A | |
| SCHEMBL31079384 | 0.86 | ASIC3 (0.37) | ASIC3WDR5PDE3BPDE3AMAPKAPK2 | |
| SCHEMBL29963694 | 0.84 | SMARCA2 (0.38) | ASIC3WDR5 | |
| SCHEMBL31079233 | 0.82 | MAPKAPK2 (0.38) | MAPKAPK2 | |
| SCHEMBL31079368 | 0.82 | ASIC3 (0.49) | ASIC3WDR5PDE3BPDE3AMAPKAPK2 | |
| SCHEMBL29964120 | 0.81 | DRD2 (0.38) | TLR7DRD2MAPKAPK2 | |
| SCHEMBL29964885 | 0.81 | MAPKAPK2 (0.36) | WDR5MAPKAPK2 | |
| SCHEMBL31079214 | 0.81 | ASIC3 (0.41) | ASIC3WDR5PDE3BPDE3AMAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | CMPK1, WNK1, AAK1 | ASIC3 3017/4885TLR7 3919/4885WDR5 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.